Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

NCT02588092 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

35

Enrollment

INDUSTRY

Sponsor class

Stopped Slow enrollment

Conditions

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia

Interventions

DRUG: ADCT-301

Sponsor

ADC Therapeutics S.A.